Compare Amphastar Pharmaceuticals Inc (AMPH) vs Blackrock Inc (BLK) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

BlackRock (BLK) trades at $1,036.11, up 1.61% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $24.22B revenue and 24.4% net margin. Recent developments include the launch of a new Nasdaq-100 ETF challenging Invesco QQQ, with Q2 2026 earnings expected on July 15.

Outlook remains positive with 76% analyst buy ratings and $1,270 consensus price target representing 22.6% upside. Key risks include market volatility affecting asset management fees and competitive pressure in ETF space. The company's pivot to private markets and AI-driven growth initiatives provide long-term opportunities.